Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brookfield Infrastructure Partners LP (BIP) vs BioNTech SE - ADR (BNTX) Price & Performance

Brookfield Infrastructure Partners LPTrade
BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

Brookfield Infrastructure Partners LP vs BioNTech SE - ADR — how do they compare? Brookfield Infrastructure Partners LP trades at $39.54 (market cap $18.10B), while BioNTech SE - ADR trades at $92.94 (market cap $23.31B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Brookfield Infrastructure Partners LP pays a 4.62% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BIPBNTX
Market Cap
$18.10B$23.31B
Sector
IndustrialsHealth
52-Week High
$42.62$119.34
52-Week Low
$29.81$83.89
Enterprise Value
$77.05B$6.60B
Dividend Yield
4.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brookfield Infrastructure Partners LP

Brookfield Infrastructure Partners (BIP) trades at $39.55, up 4.13% in the last session, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with positive cash flow trends and a 6.97 EV/EBITDA valuation. News highlights dividend appeal and corporate simplification efforts, while institutional interest remains robust.

Outlook is cautiously optimistic given high analyst buy ratings and a $44.67 price target, but risks include earnings volatility and margin pressure. The stock offers income potential with dividends, though net income declined to $652M in 2026. Investors should weigh solid infrastructure assets against execution challenges.

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Returns comparison

Trailing returns across standard periods

About Brookfield Infrastructure Partners LP

Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.

Read more on BIP

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX